Richtlijnen - AZ Sint-Lucas
Richtlijnen - AZ Sint-Lucas
Richtlijnen - AZ Sint-Lucas
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
imatinib with long-term follow-up.Miettinen M, Makhlouf H, Sobin LH, Lasota J.<br />
J. Clin. Oncology 2006 May 20;24(15):2325-31. Surgical management of advanced gastrointestinal<br />
stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.Raut CP,<br />
Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM<br />
Eur. J. Cancer 2006 May;42(8):1093-103. Epub 2006 Apr 18. KIT mutations and dose selection for<br />
imatinib in patients with advanced gastrointestinal stromal tumours.<br />
Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY,<br />
Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I; EORTC<br />
Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials<br />
Group<br />
Lancet 2006 Oct 14;368(9544):1329-38. Efficacy and safety of sunitinib in patients with advanced<br />
gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.Demetri<br />
GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR,<br />
Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.<br />
J. Clin. Oncol. May 1, 2007 vol. 25 no. 13 1753-1759 . Correlation of Computed Tomography and<br />
Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor<br />
Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography<br />
Response Criteria . Haesun Choi , Chuslip Charnsangavej, Silvana C. Faria, Homer A. Macapinlac,<br />
Michael A. Burgess, Shreyaskumar R. Patel, Lei L. Chen, Donald A. Podoloff and Robert S.<br />
Benjamin , Hohenberger P, Eisenberg B.<br />
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol<br />
25, No 18S (June 20 Supplement), 2007: 10004Comparison of two doses of imatinib for the<br />
treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis<br />
based on 1,640 patients (pts)M. M. Van Glabbeke, K. Owzar, C. Rankin, J. Simes, J. Crowley and<br />
GIST Meta-analysis Group (MetaGIST)<br />
J. Clin. Oncology 2008 Feb 1;26(4):626-32. Phase III randomized, intergroup trial assessing<br />
imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal<br />
stromal tumors expressing the kit receptor tyrosine kinase: S0033.<br />
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell<br />
VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.<br />
Annals Oncology 2009 May;20 Suppl 4:64-7. Gastrointestinal stromal tumours: ESMO clinical<br />
recommendations for diagnosis, treatment and follow-up. Casali PG, Jost L, Reichardt P,<br />
Schlemmer M, Blay JY; ESMO Guidelines Working Group.<br />
Lancet 2009 Mar 28;373(9669):1097-104. Epub 2009 Mar 18. Adjuvant imatinib mesylate after<br />
resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind,<br />
placebo-controlled trial.Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri<br />
GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan<br />
BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST<br />
Study Team.
Change language